US5978698A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Angioplasty procedure using nonionic contrast media
Assignee: Medicure International Inc
•
Filing: 1997-10-08
•
Granted: 1999-11-02
•
Expires: 2017-10-08
Abstract
Abstract A method for treating patients in need of percutaneous transluminal coronary angioplasty which comprises administering nonionic contract media to the patient and treating the patient with a fibrinogen receptor antagonist.
Inventors
- 👤 Frederic L. Sax
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 17:16
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/001; A61K49/0013; A61K49/0017
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
95 words
A method for treating a patient having coronary artery blockage which comprises a) introducing nonionic contrast dye into the coronary artery having blockage to image the blockage, b) administering a fibrinogen receptor antagonist to the patient, and inserting a balloon catheter into the blockage and inflating the balloon at the location of the blockage to revascularize the artery, and c) administering fibrinogen receptor antagonist to the patient following balloon inflation wherein the fibrinogen receptor antagonist is administered in a therapeutically effective amount sufficient to provide at least 70% inhibition of fibrinogen binding to GP IIb/IIIa.
Claim 2
Independent Claim
95 words
A method for treating a patient having coronary artery blockage which comprises a) introducing nonionic contrast dye into the coronary artery having blockage to image the blockage, b) administering a fibrinogen receptor antagonist to the patient, and inserting a balloon catheter into the blockage and inflating the balloon at the location of the blockage to revascularize the artery, and c) administering fibrinogen receptor antagonist to the patient following balloon inflation wherein the fibrinogen receptor antagonist is administered in a therapeutically effective amount sufficient to provide at least 70% inhibition of fibrinogen binding to GP IIb/IIIa.
Claim 3
Dependent Claim
29 words
A method of claim 1 wherein the fibrinogen receptor antagonist is administered to the patient according to step c) for a period of time of at least 24 hours.
Claim 4
Dependent Claim
13 words
A method of claim 1 wherein the fibrinogen receptor antagonist is orally administered.
Claim 5
Dependent Claim
31 words
A method of claim 3, wherein the fibrinogen receptor antagonist is selected from the group consisting of 2(S)-[(p-Toluenesulfonyl)amino]-3-[[[5,6,7,8-tetrahydro-4-oxo-5-[2-(piperidin-4-yl)ethyl]-4H-pyrazolo-[1,5-a][1,4]diazepin-2-yl]carbonyl]-amino]propionic acid, Methyl-N 3 -[2-{3-(4-formamidinophenyl)-isoxazolin-5(R)-yl}-acetyl]-N 2 -(n-butyloxycarbonyl)-2,3-(S)-diaminopropionate acetate salt, Ethyl 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate, and, (R)-methyl-3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine monoacetate.
Claim 6
Dependent Claim
13 words
A method of claim 1 wherein the fibrinogen receptor antagonist is intravenously administered.
Claim 7
Dependent Claim
37 words
A method of claim 5, wherein the fibrinogen receptor antagonist is selected from the group consisting of Mpr-(Acetimidyl-Lys)-Gly-Asp-Trp-Phe-Cys-NH 2 , Mpr-(Acetimidyl-Lys)-Gly-Asp-Trp-Phe-Pen-NH 2 , Mpr-(Phenylimidyl-Lys)-Gly-Asp-Trp-Phe-Pen-NH 2 , Mpr-(Phenylimidyl-Lys)-Gly-Asp-Trp-Phe-Cys-NH 2 , N-Methyl-D-phenylalanyl-N-[(1S)-1-formyl-4-guanidinobutyl]-L-prolinamide, ((1-(2-((4-(aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)-(S)-acetic acid, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidnyl)-1-(cyclohexylmethyl)-2-oxoethyl)-(R,S)-glycine, and (2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid hydrochloride.
Claim 8
Dependent Claim
14 words
A method of claim 5 wherein the fibrinogen receptor antagonist is Mpr-(Har)-G-D-W-P-C-NH 2 .
References Cited (Backward Citations)
US5292756A
Cited
US5281585A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-11-01 | 2003-05-03 | 2003-11-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-11-01 | 2007-05-03 | 2007-11-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-11-01 | 2011-05-03 | 2011-11-02 | $7700.00 | Window Closed / Lapsed |